Expert opinion on Tilarginine in the treatment of shock

Expert Opinion on Investigational Drugs

Volumn 17, Issue 10, 2008, Pages 1573-1580

  Howes, Laurence Guy ^a   Brillante, Divina Gracila ^b  

^a GRIFFITH UNIVERSITY   (Australia)

^b ST GEORGE HOSPITAL   (Australia)

Author keywords

Cardiovascular shock; L NMMA; Nitric oxide; Septic shock; Tilarginine

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; INOTROPIC AGENT; N(G) METHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; PHENYLEPHRINE; PLACEBO;

ACUTE HEART FAILURE; ADRENERGIC SYSTEM; ARTICLE; CARDIOGENIC SHOCK; CLINICAL TRIAL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EXCRETION; DRUG FATALITY; DRUG HALF LIFE; DRUG SAFETY; DRUG WITHDRAWAL; HEART ARRHYTHMIA; HEART DISEASE; HEART INDEX; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERPOLARIZATION; LOW DRUG DOSE; LUNG VASCULAR RESISTANCE; METABOLIC ACIDOSIS; NONHUMAN; PROTEIN FUNCTION; PULMONARY HYPERTENSION; SEPTIC SHOCK; SINGLE DRUG DOSE; SYSTEMIC VASCULAR RESISTANCE; VASOCONSTRICTION; VASODILATATION; VEIN TONE;

ANIMALS; ENZYME INHIBITORS; HEART; HUMANS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OMEGA-N-METHYLARGININE; SHOCK, CARDIOGENIC; SHOCK, SEPTIC; SYMPATHETIC NERVOUS SYSTEM;

EID: 53049108027     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.17.10.1573     Document Type: Article

References (47)

1. Forstermann U, Closs EI, Pollock JS, et al. Nitric oxide synthase inhibitors. Charachterization, purification, molecular cloning and functions. Hypertension 1994;23(6 Pt 2):1121-31
2. Sharma JN, Al-Omran A, Parvathy SS. Role of nitric oxide in inflammatory diseases. Inflammopharmacology 2007;15(6):252-9
3. Boer R, Ulrich W, Klein T, et al. The inhibitory potency of arginine substrate site nitric oxide synthase inhibitors determined by their affinity towards the different isoenzymes. Mol Pharmacol 2000;58:1026-34
4. Leiper J, Vallance P. Biological significance of endogenous methylarginines that inhibit nitric oxide synthases. Cardiovasc Res 1999;43(3):542-8
5. Giannotti G, Landmesser U. Endothelial dysfunction as an early sign of atherosclerosis. Herz 2007;32(7):568-72
6. Mayer BX, Mensik C, Krishnaswami S, et al. Pharmacokinetic-pharmacodynamic profile of systemic nitric oxide-synthase inhibition with L-NMMA in humans. Br J Clin Pharmacol 1999;47(5):539-44
7. Hussein Z, Beerahee M, Grover R, et al. Pharmacokinetics of the nitric oxide synthase inhibitor L-NG-methylarginine hydrochloride in patients with septic shock. Glaxo Wellcome International Septic Shock Study Group. Clin Pharmacol Ther 1999;65(1):1-9
8. Kiely DG, Lee AF, Struthers AD, Lipworth BJ. Nitric oxide: an important role in the maintenance of systemic and pulmonary vascular tone in man. Br J Clin Pharmacol 1998;46(3):263-6
9. Stamler JS, Loh E, Roddy MA, et al. Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans. Circulation 1994;89(5):2035-40
10. Brett SE, Cockcroft JR. Mant, TG, et al. Haemodynamic effects of inhibition of nitric oxide synthase and of L-arginine at rest and during exercise. J Hypertens 1998;16(4):429-35
11. Archer SL, Michelakis ED. An evidence-based approach to the management of pulmonary arterial hypertension. Curr Opin Cardiol 2006;21(4):385-92
12. Stewart AD, Millasseau SC, Kearney MT, et al. Effects of inhibition of basal nitric oxide synthesis on carotid-femoral pulse wave velocity and augmentation index in humans. Hypertension 2003;42(5):915-8
13. Ferguson JW, Dover AF, Chia S, et al. Inducible nitric oxide synthase activity contributes to the regulation of peripheral vascular tone in patients with cirrhosis and ascites. Gut 2006;55(4):542-6
14. Titheradge MA. Nitric oxide in septic shock. Biochim Biophys Acta 1999;1411(2-3):437-55
15. Schindler C, Dobrev D, Grossmann M, et al. Mechanisms of beta-adrenergic receptor-mediated venodilation in humans. Clin Pharmacol Ther 2004;75(1):49-59
16. Nightingale AK, Blackman DJ, Ellis GR, et al. Preservation of venous endothelial function in the forearm venous capacitance bed of patients with chronic heart failure despite arterial endothelial dysfunction. J Am Coll Cardiol 2001;37(4):1062-8
17. Prendergast BD, Sagach VF, Shah AM. Basal release of nitric oxide augments the Frank-Starling response in the isolated heart. Circulation 1997;96(4):1320-9
18. Harrison RW, Thakkar RN, Senzaki H, et al. Relative contribution of preload and afterload to the reduction in cardiac output caused by nitric oxide synthase inhibition with L-N(G)-methylarginine hydrochloride 546C88. Crit Care Med 2000;28(5):1263-8
19. Rassaf T, Poll LW, Brouzos P, et al. Positive effects of nitric oxide on left ventricular function in humans. Eur Heart J 2006;27(14):1699-705
20. Amrani M, O'Shea J, Allen NJ, et al. Role of basal release of nitric oxide on coronary flow and mechanical performance of the isolated rat heart. J Physiol 1992;456:681-7
21. Chowdhary S, Marsh AM, Coote JH, et al. Nitric oxide and cardiac muscarinic control in humans. Hypertension 2004;43(5):1023-8
22. Julou-Schaeffer G, Gray GA, Fleming I. Loss of vascular responsiveness induced by endotoxin involves l-arginine pathway. Am J Physiol 1990;259(4 Pt 2):H1038-43
23. Geng YJ, Hansson GK, Holme E. Interferon gamma and tumor necrosis factor synergise to induce, nitric oxide production and inhibit mitochondrial respiration in vascular smooth muscle cells. Circ Res 1992;71:1268-76
24. Mak S, Overgaard CB, Newton GE. Effect of vitamin C and L-NMMA on the inotropic response to dobutamine in patients with heart failure. Am J Physiol 2005;289(6):H2424-8
25. Charkoudian N, Joyner MJ, Barnes SA, et al. Relationship between muscle sympathetic nerve activity and systemic hemodynamics during nitric oxide synthase inhibition in humans. Am J Physiol 2006;291(3):H1378-83
26. Sartori C, Lepori M, Scherrer U. Interaction between nitric oxide and the cholinergic and sympathetic nervous system in cardiovascular control in humans. Pharmacol Ther 2005,106(2):209-20
27. Bakker J, Grover R, McLuckie A, et al.; Glaxo Wellcome International Septic Shock Study Group. Administration of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002). Crit Care Med 2004;32(1):1-12
28. Katz SD, Krum H. Acetylcholine-mediated vasodilation in the forearm circulation of patients with heart failure: indirect evidence for the role of endothelium-derived hyperpolarizing factor. Am J Cardiol 2001;87(9):1089-92
29. Cobb J, Danner R. Nitric oxide and septic shock. JAMA 1996;275:1192-6
30. Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. N Engl J Med 2001;345:588-95
31. Lopez A, Lorente JA, Steingrub J, et al. Multi-center, randomised, placebo-controlled double blind study of the nitric oxide inhibitor 546C: effects on survival in patients with septic shock. Crit Care Med 2004;32:21-30
32. Pickkers P. Dorresteijn MJ, Bouw MPWJM, et al. In vitro-evidence for nitric oxide mediated calcium activated potassium channel activation during human endotoxemia. Circulation 2006; 114:414-21
33. Bhagat K, Vallance P. Effects of cytokines on nitric oxide pathways in human vasculature. Curt Opin Nephrol Hypertens 1999;8:89-96
34. Pullamsetti SS, Mating D, Ghofrani HA, et al. Effect of nitric oxide synthase (NOS) inhibition on macro and microcirculation in a model of rat endotoxic shock. Thromb Haemostasis 2006;95:591-2
35. Statman R, Cheng W, Cunningham JN, et al. Nitric oxide inhibition in the treatment of the sepsis syndrome is detrimental to tissue oxygenation. J Surg Res 1994;57(1):93-8
36. Rees H, Monkhouse JE, Mocanda S. NG-monomethyl-L-arginine HCL (L-NMMA: 546C88) improves survival in a conscious instrumented mouse model of endotoxic shock. Endothelium 1995;3(Suppl 1):S116
37. Redl H, Schlag G, Gasser H. Treatment with the NO synthase inhibitor 546C88 twelve hours after the start of E. coli bacteraemia is beneficial in a baboon model of septic shock. Shock 1997;8(Suppl 1):51
38. Grover R, Zaccardelli D, Colice G, et al. Am open-label dose escalation study of the nitric oxide synthase inhibitor, N(G)-methyl-L-arginine hydrochloride (546C88), in patients with septic shock. Glaxo Wellcome International Septic Shock Study Group. Crit Care Med 1999;27(5):913-22
39. Watson D, Grover R, Anzueto A, et al.; Glaxo Wellcome International Septic Shock Study Group. Cardiovascular effects of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) in patients with septic shock: results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002). Crit. Care Med. 2004;32(1):13-20
40. Hochman JS. Cardiogenic shock complicating acute myocardial infarction: expanding the paradigm. Circulation 2003; 107(24):2998-3002
41. Cotter G, Kaluski E, Blatt A, et al. L-NMMA (a nitric oxide synthase inhibitor) is effective in the treatment of cardiogenic shock. Circulation 2000;101(12):1358-61
42. Cotter G, Kaluski E, Milo O, et al. LINCS: L-NAME (a NO synthase inhibitor) in the treatment of refractory cardiogenic shock: a prospective randomized study. Eur Heart J 2003;24(14):1287-95
43. Alexander JH, Reynolds HR, Stebbins AL, et al.; Triumph Investigators. Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. JAMA 2007;297(15):1657-66
44. Dzavik V, Cotter G, Reynolds HR, et al.; SHould we inhibit nitric Oxide synthase in Cardiogenic shocK 2 (SHOCK-2) investigators. Effect of nitric oxide synthase inhibition on haemodynamics and outcome of patients with persistent cardiogenic shock complicating acute myocardial infarction: a phase II dose-ranging study. Eur Heart J 2007;28(9):1109-16
45. Garvey EP, Oplilnger JA, Furfine ES, et al. 1400W is a slow, tight binding, and highly selective inhibitor of inducible nitric-oxide synthase in vitro and in vivo. J Biol Chem 1997-272(8):4959-63
46. Heemskirk S, Pickkers P, Bouw MP, et al. Upregulation of renal inducible nitric oxide synthase during human endotoxemia is associated with proximal tubule injury. Clin J Am Soc Nephrol 2006; 1:853-62
47. Naka M, Nanbu T, Kobayashi K, et al. A potent inhibitor of inducible nitric oxide synthase, ONO-1714, a cyclic amidine derivative. Biochem Biophys Res Commun 2000;270:663-7